Dotinurad Treatment for Patients With Hyperuricemia Complicating CKD
Open Access
- 5 April 2025
- journal article
- Published by Elsevier in Kidney International Reports
- Vol. 10 (6) , 1711-1720
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Efficacy of dotinurad in patients with severe renal dysfunctionClinical and Experimental Nephrology, 2023
- Comparative study of a novel selective urate reabsorption inhibitor “dotinurad” among patient groups with different stages of renal dysfunctionClinical and Experimental Nephrology, 2021
- Factors associated with achieving target serum uric acid level and occurrence of gouty arthritis: A retrospective observational study of Japanese health insurance claims dataPharmacoepidemiology and Drug Safety, 2020
- 2020 American College of Rheumatology Guideline for the Management of GoutArthritis Care & Research, 2020
- Dotinurad versus benzbromarone in Japanese hyperuricemic patient with or without gout: a randomized, double-blind, parallel-group, phase 3 studyClinical and Experimental Nephrology, 2020
- A non-inferiority study of the novel selective urate reabsorption inhibitor dotinurad versus febuxostat in hyperuricemic patients with or without goutClinical and Experimental Nephrology, 2020
- Open-label study of long-term administration of dotinurad in Japanese hyperuricemic patients with or without goutClinical and Experimental Nephrology, 2019
- Effects of mild and moderate renal dysfunction on pharmacokinetics, pharmacodynamics, and safety of dotinurad: a novel selective urate reabsorption inhibitorClinical and Experimental Nephrology, 2019
- Essential points from Evidence-based Clinical Practice Guidelines for Chronic Kidney Disease 2018Clinical and Experimental Nephrology, 2018
- Allopurinol and Progression of CKD and Cardiovascular Events: Long-term Follow-up of a Randomized Clinical TrialAmerican Journal of Kidney Diseases, 2015